Previous Article | Next Article 
Journal of Clinical Microbiology, March 1999, p. 490-496, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Detection and Quantitation of Human Papillomavirus
by Using the Fluorescent 5' Exonuclease Assay
Agnetha
Josefsson,1
Ken
Livak,2 and
Ulf
Gyllensten1,*
Department of Genetics and Pathology, Unit of
Medical Genetics, University of Uppsala, S-751 23 Uppsala,
Sweden,1 and
Applied Biosystems Division
of Perkin-Elmer, Inc., Foster City, California2
Received 13 May 1998/Returned for modification 20 July
1998/Accepted 13 October 1998
 |
ABSTRACT |
A method for the detection and quantitation of oncogenic human
papillomavirus (HPV) was developed by using the fluorescent 5'
exonuclease assay. The method is based on the amplification of a 180-bp
fragment from the 3' part of the E1 open reading frame in a single PCR
with type-specific probes for HPV types 16, 18, 31, 33, and 35. The
probes can be used separately or in combinations of up to three probes
per assay. Quantitation over a range of 101 to
106 initial HPV copies was possible by using real-time
detection of the accumulation of fluorescence with cycle number.
Reconstitution experiments, performed to mimic mixed infections, showed
that individual HPV types can be detected down to a ratio of about 1%
in a mixture. The performance of the assay depends on DNA quality, the
presence of PCR inhibitors, and the number of different probes used
simultaneously. This homogeneous assay provides a fast and sensitive
way of screening for oncogenic HPV types in biopsy specimens as well as
cervical smear samples. The closed-tube nature of the assay and the
inclusion of uracil N'-glycosylase reduces cross contamination of PCR products to a minimum. A similar assay for
-actin was used in parallel for quantitation of genomic DNA. After
normalizing the samples for genomic DNA content, the mean number of HPV
copies per cell could be calculated.
 |
INTRODUCTION |
Infection with certain types of
human papillomavirus (HPV) has been shown to be the single most
important risk factor for the development of cervical cancer
(15). More than 70 different types of HPV have been
described, and about 30 of these infect the internal and external
genitalia. Approximately 95% of biopsy specimens from patients with
cervical cancer have been found to contain DNA of high-risk HPV types,
most commonly HPV type 16 (HPV-16), followed by HPV types 18, 31, and
45 (3). Among the low-risk types, HPV-6 and HPV-11 are
associated with condylomata acuminata but only rarely with carcinogenic
progression (3, 18, 30, 34).
Given the importance of HPV infection as a risk factor for cervical
cancer, considerable efforts have been made in the development of
techniques for the detection of the virus as well as the associated cellular changes (11, 13, 17). Serological detection
methods, in which conformational antibodies against self-assembled
capsid proteins are used, have been employed to detect present or
recent infection with HPV (5, 18). Since not every infected
individual develops antibodies, this method has certain limitations
(12). Other methods have been based on detection of viral
nucleic acid by either in situ hybridization (6, 33),
restriction fragment length polymorphism analysis and Southern blot
analysis (4, 27, 31), hybrid capture (in which a DNA-RNA
heteroduplex is recognized by monoclonal antibodies) (4, 22,
23), and finally, PCR. Many of the PCR systems for HPV detection
involve an amplification step followed by any of a number of methods
for distinguishing different HPV types (28, 29). The most
common HPV DNA amplification systems are based either on the MY09-M411
primer pair (26) or the GP5+-GP6+ primer pair
(8); both of these target the L1 reading frame. These primer
pairs have been used in combination with microtiter plate hybridization
(16) or with reverse dot blots (13a) for
identification of viral subtype. A nested PCR has sometimes been used
to increase the sensitivity of the assay when samples with limited DNA
content, such as Formalin-fixed biopsy specimens and archival
Papanicolaou (Pap)-stained smears (35), are analyzed.
To investigate aspects of the natural history of cervical cancer, such
as the variation in the amount of HPV in low-grade lesions versus the
amount in high-grade lesions, a highly sensitive detection system that
allows the quantitation of viral copy numbers is required; none of the
presently available methods appear to be suitable for such analyses. We
have therefore converted our previously developed PCR assay for the E1
reading frame (35) to a detection system in which the 5'
exonuclease assay is used (14). The 5' exonuclease assay is
based on the ability of the 5' to 3' exonuclease activity of
Taq polymerase to cleave a dually labeled, nonextendible
hybridization probe during the extension phase of the PCR (14, 19,
21). The probe has one fluorescent dye attached as a reporter at
the 5' end, and in the undigested form, the emission from this reporter
dye is quenched by a second fluorescent dye, which is attached to the
3' end. Concomitant with the accumulation of PCR product, there is a
release of the reporter dye. In this report we describe the
characteristics of our HPV assay based on the 5' exonuclease method.
Recently, a fluorescent 5' exonuclease assay for the detection of HPV
with a series of type-specific PCRs was described (32). Our
system differs from that of Swan et al. (32) in several
ways. In particular, (i) we perform a single PCR and for detection use
multiple HPV type-specific probes labeled with different fluorescent
dyes instead of multiple PCRs and a single probe for each HPV type, and
(ii) most importantly, we use real-time detection of the accumulation of fluorescence rather than a measure of the fluorescence at a single
cycle number (endpoint reading) to quantitate the initial viral copy numbers.
 |
MATERIALS AND METHODS |
DNA extraction.
High-molecular-weight DNA was isolated from
blood samples by a standard protocol that included proteinase K
treatment, followed by phenol-chloroform extraction and ethanol
precipitation (25). DNA extraction from archival
formalin-fixed biopsy specimens was performed by using a
deparaffination step with xylene, successive ethanol washes followed by
proteinase K digestion, phenol-chloroform extraction, and finally,
ethanol precipitation (17, 20). DNA from Pap-stained smears
was purified by a modification (17) of the protocol
described by Chua and Hjerpe (7). This protocol included
xylene incubation, destaining, proteinase K treatment (60°C for a
minimum of 1 h), and subsequently, a transfer of cells to sterile
Eppendorf tubes. Saturated ammonium acetate was then added to
precipitate the protein. The DNA supernatant was recovered with
ethanol; and the pellet was washed with 70% ethanol, dried, and
dissolved in 200 µl of TE-low (10 mM Tris-HCl [pH 7.4], 0.1 mM EDTA).
Plasmids containing HPV types 16, 18, 31, 33, and 35 were used as
positive controls and to estimate the sensitivity of the assay (1,
9, 10, 24). The plasmids with integrated HPV were transformed
into One Shot cells (INV
F'; Invitrogen TA Cloning kit), positive
transformants were isolated and grown in 100 ml of TB (Terrific Broth)
at 37°C overnight, and plasmid DNA was extracted with the Qiagen
Maxiprep kit (Qiagen). A cell line containing integrated HPV-16 (SiHa)
was grown on a solid phase and was harvested after trypsination in 3 ml
of STV (137 mM sodium chloride, 5.4 mM potassium chloride, 5.6 mM
glucose, 6.9 mM sodium carbonate, 0.5 mM EDTA, 5 mg of phenol red per
ml) plus 1.5% trypsin for 2 min with incubation at 37°C. The cells
were then washed, first in growing medium (Dulbecco's modification of
Eagle's medium, 160 µM k-benzylpenicillin, 34.3 mM
streptomycin-sulfate, 1.99 mM glutamine, 10% newborn calf serum) and
then in 1× phosphate-buffered saline. The cell pellet was dissolved in
1 ml of phosphate-buffered saline, and the concentration of the cells
was estimated.
To study the effect of the Pap staining procedure on assay sensitivity,
microscope glass slides with SiHa cells were prepared, the cells were
stained, and the DNA was extracted by a modification (17) of
the protocol described by Chua and Hjerpe (7) as described above.
PCR.
The PCR amplification was performed in a 50-µl volume
containing 1× Taqman buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.4], 10 mM EDTA, 60 nM passive reference dye 6-carboxytetramethyl rhodamine [Rox]), 5 mM MgCl2, 0.5 mM HPV E1 5' primer (see Table 1
and below), 0.5 mM HPV E1 3' primer (see Table 1 and below), each HPV-specific dual-labeled probe at a concentration of 100 nM, dATP,
dCTP, and dGTP each at a concentration of 200 µM, 400 µM dUTP, 0.5 U of uracil N'-glycosylase (AmpErase UNG; Perkin-Elmer), 1.25 U of DNA polymerase (Amplitaq Gold; Perkin-Elmer), 124 ng of
bovine serum albumin (BSA) per µl, and 2 to 10 µl of DNA. The amount of DNA added to a PCR mixture represents 1 to 5% of the DNA
obtained from a cervical smear. The uracil N'-glycosylase was included in order to cleave potential PCR products from previous PCRs.
Individual HPV types differ substantially at the nucleotide level,
complicating the development of an HPV typing system capable of
detecting a range of genital types of HPV (2). We previously identified a region in the first part of the E1 gene that is highly conserved among genital HPV types and that is suitable as a PCR priming
site. The product generated by using this site and an adjacent priming
site is only 180 bp (35). In our previously described system
(35) we used a pair of degenerate primers (Table 1). In the present system we have
redesigned the primers to reduce the complexity of the primers added to
the PCR mixture. In the new system the 5' primer mix consisted of only
two primers (HPVE116L and HPVE118L) and the 3' primer mix consisted of
three primers (HPVE116R, HPVE118R, and HPVE1RE) (Table 1). Each of the
primer mixtures contained an equimolar mixture of the oligonucleotides included in the mixture.
Probes.
The sequences for the probes used in the
fluorescence assay were modified from those used in our previous HPV
detection system (35). The probes were 30 to 33 bp in length
to ensure a higher melting temperature for the probes than for the
primers. A fluorescent reporter dye was covalently linked to the 5'
end, and a quencher dye was linked to the 3' end. As reporter dyes we
used 6-carboxyfluorescein (FAM), tetrachloro-6-carboxyfluorescein
(TET), or hexachloro-6-carboxyfluorescein (HEX). As a quencher we used
6-carboxytetramethylrhodamine (TAMRA; Applied Biosystems Division of
Perkin-Elmer, Inc., Foster City, Calif.) (Table
2). The probes were made so that a
guanosine was avoided at the most 5' end and were purified by
high-pressure liquid chromatography prior to use. The probes were found
to be sensitive to the number of cycles of freezing and thawing. To ensure stability, fresh probe was aliquoted in an amount sufficient for
about 1 day of experiments and frozen.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Sequence, fluorescent label, and specificity of the
oligonucleotide probes used in the fluorescent 5' exonuclease
HPV assay
|
|
Amplification and detection by the 5' exonuclease method.
Amplification and detection were performed with an ABI Prism 7700 Sequence Detection System (Perkin-Elmer, Inc.). The amplification ramp
included two hold programs: (i) 2 min at 50°C to activate the uracil
N'-glycosylase followed by (ii) 10 min at 95°C to
inactivate the uracil N'-glycosylase and release the
activity of the DNA polymerase. The two hold steps were followed by a
two-step cycle consisting of 15 s at 95°C and 1 min at 50°C
for a total of 50 cycles. Tubes that contained all PCR components but
without template DNA (denoted no-template control [NTC] reactions)
were used to ensure that the reagents were free of contamination.
Calculations.
The threshold cycle number
(Ct) was calculated with Sequence Detection
System software (Applied Biosystems Division, Perkin-Elmer, Inc.) and
an automatic setting of the baseline (10 standard deviations [SDs]
above the background in the first 3 to 15 cycles). Standard curves were
generated by plotting the Ct values against the
log of the copy numbers and the copy numbers for unknown samples
inferred from the regression line.
 |
RESULTS |
Specificity of detection system.
The amplification
efficiencies of the new primer system and that described previously
(35) were similar. In the fluorescent 5' exonuclease assay
we have exclusively used the new primer set.
We first tested the ability of the probes for HPV types 16, 18, 31, 33, and 35 to discriminate between different HPV types. All probes showed
an excellent ability to discriminate the correct from the incorrect HPV
type, and no signal (i.e., Ct = 50) was seen
with a mismatched combination of HPV DNA and probe (data not shown).
When a large number of NTC reactions was performed, the probe for
HPV-16 occasionally yielded a positive Ct value, despite the lack of added DNA template. This occurred in about 10% of
the NTC reactions. When NTC reactions were run without the addition of
uracil N'-glycosylase and the products of positive NTC
reactions were examined electrophoretically, no product of the size
expected for an HPV amplicon was found. Thus, the positive signal is
likely to have been generated from an artifact product, such as a
primer-dimer, rather than because of low levels of contamination with
genomic DNA. Comparisons between primer and probe sequences did not
reveal any regions with substantial homology, which could be
responsible for the generation of such fluorescence. As can be seen
from the amplification plot, HPV-16 artifact signals from NTC reactions
are easily distinguished from the signal from HPV templates by the very
steep amplification slope (Fig. 1). Also, the Ct values for specimens with positive NTC
reactions were generally very high (Ct > 40)
compared to those for smear or biopsy specimens. None of the other HPV
probes tested gave any signal in the NTC reactions.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of the amplification plots for HPV-16 plasmid
DNA (106 starting copies), a cervical smear DNA, and two
NTCs yielding positive signals. All reactions were performed with the
HPV-16 probe only. Delta Rn, reporter fluorescence of sample minus
fluorescence of background (cycles 3 to 15).
|
|
Quantitation.
The sensitivity of the assay was studied with
plasmid DNA with cloned HPV types 16, 18, 31, 33, and 35. Plasmid copy
numbers were calculated from optical density (OD) measurements, and
dilution series were made with 106 to 100 HPV
copies (except for HPV-18, for which the dilution series was from
108 to 101 copies). The plasmids with cloned
HPV were then mixed with a solution of 100 pg of high molecular weight
human genomic DNA (lacking HPV inserts) per µl in order to mimic the
complex nucleic acid environment present in an amplification from
genomic DNA (biopsy specimens and cervical smears). To generate the
standard curve for each HPV type, a minimum of five replications of
each HPV copy number were performed. A highly significant linear
relationship was found between the log of the input HPV copy number and
threshold cycle (Ct) for all HPV types tested
(Fig. 2). The slopes for the different
HPV types were similar, but the intercepts differed, which is
indicative of a difference in sensitivity. This could reflect either
the efficiency of amplification of different HPV types or differences
in efficiency of hybridization of the individual probes. Nevertheless,
with the type-specific standard curves, quantitation of each HPV type
was possible. The SD of the Ct values was found
to be between 0.3 and 1.7 cycles, with the higher values seen for the
lower copy numbers (Table 3). These SD
values correspond to a variation in the estimated copy number of about
10 to 40%.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Standard curves generated for HPV types 16, 18, 31, 33, and 35. Dilution series were made with 106 to
100 HPV copies (except for HPV-18, for which the dilution
series was from 108 to 101 copies). Linear
regression was based on the titration series of HPV plasmid DNA in a
background of 100 pg of genomic DNA per µl. Each curve is based on an
average of 5 to 10 replicates. (A) Regression lines for HPV-16 DNA and
HPV-18 DNA. Each reaction mixture contained only a single probe for
either HPV-16 or HPV-18. (B) Regression lines for HPV-31 DNA, HPV-33
DNA, and HPV-35 DNA. Each reaction mixture contained only a single
probe (for HPV-31, HPV-33, or HPV-35).
|
|
Detection of infections with multiple HPV types.
In a previous
study (35) about 5% of the biopsy specimens from patients
with cervical cancer were found to be infected with several HPV types.
The ability of the fluorescent 5' exonuclease assay to detect multiple
infections was studied by mixing HPV plasmids in different combinations
in a background of 100 pg of high-molecular-weight genomic DNA per
µl. For instance, HPV-18 DNA was titrated from 106 to
100 copies in a constant background of 103
copies of HPV-16 DNA and was detected with a mixture of probes for
HPV-16 and HPV-18 (Fig. 3). The results
do not indicate a significant change in sensitivity for the detection
of HPV-18 in the background of HPV-16 compared to the sensitivity from
the standard curve (Fig. 2). HPV-18 could be identified down to a fraction of about 1% of the total number of HPV copies (Fig. 3). Similar results were obtained with several other combinations of HPV
types (data not shown).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of a synthetic mixture of HPV types. Titration
of HPV-18 plasmid DNA (106 to 100 copies) in a
background of 103 copies of HPV-16 plasmid DNA. The
reaction mixtures contained probes for both HPV-16 and HPV-18.
|
|
Effect of DNA quality on sensitivity.
To study the effect of
DNA quality on the performance of the assay, we compared standard
curves for the amplification of
-actin using a fluorescent probe
(Applied Biosystems Division, Perkin-Elmer, Inc.). The following DNA
sources were used: (i) high-molecular-weight human genomic DNA purified
from blood, (ii) DNA from an archival formalin-fixed, paraffin-embedded
biopsy sample, and (iii) DNA from fresh cells prepared on microscope
slides to mimic cervical smear samples and by fixation and staining
methods identical to those used for cervical smear samples. DNA from
the formalin-fixed, paraffin-embedded sample showed a very low
amplification efficiency (high Ct value)
compared to those for high-molecular-weight DNA samples with the same
amount of DNA (on the basis of the OD measurement) (Fig.
4A). The Ct values
for DNA from the formalin-fixed, paraffin-embedded sample were
equivalent to a starting copy number of about 1/100 to 1/1,000 of that
estimated from the OD measurement for the sample (Fig. 4A). Thus, the
procedure for formalin fixation has a very strong effect on the
amplification efficiency. To test the amplification efficiency with DNA
from stained cervical smears, we used cells in cell culture and
prepared series of smears containing different numbers of cells that
were treated by the Pap staining procedure. Three to five replicates of
each experiment were performed. No difference was found between the
artificially made smears treated with the Pap stain and the
high-molecular-weight genomic DNA samples, up to about 5 × 103 cells (Fig. 4B). With higher cell numbers, the Pap
staining procedure had an adverse effect on the efficiency of the
assay, and complete inhibition was seen for 5 × 104
cells (Fig. 4B). Since such inhibition is presumably caused by components of the Pap stain remaining in the DNA preparation and could
not be removed by phenol-chloroform extraction, we investigated a
number of additives that could remove the inhibitory effect. The
addition of BSA at a concentration of 124 ng/µl to the PCR mixture
entirely removed the inhibitory effect (data not shown). At much higher
concentrations the BSA showed an inhibitory effect of its own. For
cervical smears with a high Ct value
(Ct > 40), the effect of the addition of BSA
was pronounced (data not shown). Therefore, for PCR assays performed
with cervical smears, as well as with several other types of clinical
samples, we routinely add BSA to a final concentration of 124 ng/µl.
This concentration of BSA does not reduce the efficiency of
amplification for samples with no inhibitors, such as samples with
high-molecular-weight genomic DNA.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of DNA quality on signal release in the -actin
assay. (A) Comparison of the linear regression lines for a titration of
high-molecular-weight (HMW) DNA (1.5 × 105 to
1.5 × 100 copies) extracted from blood and titration
series of DNA from archival formalin-fixed biopsy specimens (1.5 × 105 to 1.5 × 100 copies). The curves
are based on three to five replicates. Only the -actin probe was
used for detection in each reaction mixture. (B) Comparison of
titration series of DNA from formalin-fixed biopsy specimen (1.5 × 105 to 1.5 × 100 copies),
high-molecular-weight (HMW) DNA isolated from blood (1.5 × 105 to 1.5 × 100 copies), and a titration
series of Pap-stained DNA (1 × 105 to 5 × 101 copies) from a cell line applied on a microscope slide.
The curves are based on three to five replicates. Only the -actin
probe was used for detection. The two open triangles at log copies of
4.5 and 5 have not been connected with a line, since no signal was
obtained at a Ct of 60 (maximum number of
cycles).
|
|
Mixed probe assay.
Since, in principle, up to three dyes can
be detected in the same PCR, we investigated the effect of using
multiple probes in each PCR on the sensitivity of detection of
individual HPV types. Plasmids with HPV DNA were added in a titration
series from 106 to 100 copies in a background
of genomic DNA and with different combinations of probes. First, we
compared the detection of HPV-35 DNA (106 to
100 copies) with a mixture of probes for HPV types 16, 33, and 35 compared to the detection of HPV-35 DNA (106 to
100 copies) with only the HPV-35 probe (Fig.
5A). A somewhat reduced sensitivity for
the detection of HPV-35 was seen by the mixed probe assay. However, the
assay was linear over the entire spectrum of copy numbers studied.
Similarly, the detection of HPV-16 DNA (106 to
100 copies) was studied with a mixture of probes for HPV
types 16, 33, and 35 and was compared to the detection of HPV-16 DNA
with only the HPV-16 probe (Fig. 5B). The sensitivity of the
three-probe assay was similar to that of the single-probe assay, in
particular at low copy numbers, but the relationship between copy
number and fluorescence was still linear. Similar results were obtained for the detection of HPV-31 DNA (106 to 100
copies) with a mixture of probes for HPV-18 and HPV-31 compared to the
results obtained for the detection of HPV-31 DNA (106 to
100 copies) with only the HPV-31 probe (Fig. 5C). However,
a substantial difference between the assay with a mixture of probes and
the single-probe assay was found for the detection of HPV-18. The sensitivity for the detection of HPV-18 (106 to
100 copies) was dramatically reduced when a mixture of
probes for HPV-18 and HPV-31 was used rather than when only the HPV-18
probe was used (Fig. 5D). Finally, we investigated the effect of using a mixture of HPV-16 and HPV-18 probes in the same reaction mixture. Therefore, we mixed both HPV-16 DNA and HPV-18 DNA in a parallel titration series (106 to 100 copies) with equal
amounts of DNA of the two viral types and a mixture of probes for
HPV-16 and HPV-18 (Fig. 6). For HPV-16 the slope was similar to that of the standard curve, while the sensitivity in detecting HPV-18 was reduced, and no HPV-18 signal was
detected when HPV-18 was present at less than 103 copies.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 5.
Detection by mixed-probe assays. (A) Titration series of
HPV-35 DNA (106 to 100 copies) and a mixture of
probes for HPV types 16, 33, and 35 compared to titration series of
HPV-35 DNA (106 to 100 copies) and the HPV-35
probe. (B) Titration series for HPV-16 DNA (106 to
100 copies) detection and a mixture of probes for HPV type
16, 33, and 35 compared to titration series for HPV-16 DNA
(106 to 100 copies) detection and the HPV-16
probe. (C) Titration series of HPV-31 DNA (106 to
100 copies) and a mixture of probes for HPV-18 and HPV-31
compared to titration series of HPV-31 DNA (106 to
100 copies) and the HPV-31 probe. (D) Titration series of
HPV-18 DNA (106 to 100 copies) and a mixture of
probes for HPV-18 and HPV-31 compared to titration series of HPV-18 DNA
(106 to 100 copies) and the HPV-18 probe.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of HPV-16 DNA and HPV-18 DNA in a titration
series of 106 to 100 copies with equal amounts
of DNA of the two types and a mixture of HPV-16 and HPV-18 probes.
|
|
Application to archival smears.
A series of 21 archival smears
previously typed by the E1 dot blot system (35) were
analyzed by the fluorescent 5' exonuclease assay. In all these smears
the typing result (with respect to HPV subtype) was identical to that
obtained previously (data not shown).
 |
DISCUSSION |
We have evaluated the use of the real-time fluorescent 5'
exonuclease assay for HPV detection and quantitation. This assay has a
number of potential advantages over existing PCR-based methods since it
(i) requires no further analysis after the amplification step, because
data collection occurs during amplification, (ii) prevents the
contamination of PCR products due to the closed-tube system used and
the inclusion of the carryover prevention enzyme uracil
N'-glycosylase in each reaction mixture, (iii) allows the use of multiple detection probes in the same reaction mixture, and (iv)
permits accurate quantitation over a very wide range of copy numbers.
The fluorescent 5' exonuclease assay was found to discriminate well
between the HPV types investigated and can be used to quantify the HPV
copy number over a wide range of HPV copy numbers. When a single type
of HPV DNA and a single probe were used, all the HPV probes clearly
discriminated among the HPV types (data not shown). Also, for all HPV
types the standard curve obtained was linear over a spectrum of
concentrations that greatly exceed the range normally found in actual
clinical samples. Thus, under these circumstances the assay is quite
suitable for use in the typing of HPV.
In certain synthetic mixtures of HPV types, made to mimic mixed
infections, we observed a reduced sensitivity for the detection of
individual HPV types, in particular, for HPV-18. In this case the
reduced sensitivity is likely to be due to a competition between the
two PCR products generated in the reaction or interference between
probes. In synthetic mixtures the individual HPV types could be
detected down to a fraction of about 1% of the total copy number, and
in certain combinations it was even possible to detect the individual
HPV types down to a fraction of 0.1% (data not shown). Thus, it should
be possible to detect mixed infections, even when the different viral
types occur in substantially different proportions. In analyzing a
series of biopsy samples we have identified a number of mixed
infections, attesting to the ability of the present assay to detect
multiple HPV types in individual samples (data not shown). The present
HPV assay can be performed either in a few reactions with multiple
probes or in a large number of reactions each with a type-specific
probe. It appears that the mixed probe assay is suitable solely for
detection and has sufficient sensitivity. However, for accurate
quantitation, the number of probes per reaction mixture may be reduced.
In our system this appears to be required only for the quantitation of HPV-18, for which the strongest reduction in sensitivity was shown when
a mixture of probes was used.
Our results point to the extensive variation in amplification
efficiency between materials that have been subjected to different staining and fixation procedures. In particular, the DNA in
formalin-fixed, paraffin-embedded tissue samples was shown to be
amplified at an efficiency equivalent to about 1/100 to 1/1,000 of that
of high-molecular-weight DNA. Thus, in analyzing formalin-fixed, paraffin-embedded samples, it is necessary to quantitate the extent of
inhibition by using, for instance, the
-actin control assay before
the pathogen titers can be accurately estimated. A similar problem may
apply to cytological Pap-stained smears. For samples with low DNA
concentrations, our results with samples mimicking Pap-stained smears
showed that they had amplification efficiencies similar to that for
high-molecular-weight DNA. However, with high DNA concentrations,
Pap-stained smears completely inhibited the PCR. This indicates that
reliable analysis of the HPV in archival smears will be possible only
if the inhibitory effect can be removed. We found that the presence of
a simple additive (BSA) at low concentrations can remove the inhibitory
effect. Since this additive does not appear to have any effect on the
efficiency of the reaction, it can be added to all reaction mixtures,
including those used to generate the standard curve. This approach
makes it possible to generate an appropriate standard curve that can be
applied to cervical smear samples. However, BSA has no effect on the
efficiency of amplification of DNA from formalin-fixed samples. For
quantitation of viral copy numbers from tissue samples in which an
additive, such as BSA, does not remove the inhibitory effect, the
standard curves used must be derived from DNA samples handled in a
manner identical to that in which the biological samples are handled.
The 5' exonuclease assay for
-actin was used in parallel with the
HPV assay to obtain an estimate of the amount of genomic DNA present in
individual smear samples. By using the
-actin copy number, which was
estimated from the standard curve, the smear samples can be normalized
for the amount of genomic DNA. On the basis of such a normalization the
variation in HPV copies per genomic DNA equivalent can be estimated
(i.e., by dividing the HPV copy number by the
-actin copy number).
Our preliminary results from the analysis of a large set of cervical
smears indicate that the Ct values for
-actin
can vary with more than six cycles between individual samples,
indicating substantial differences in the amount of genomic DNA
accessible to PCR (data not shown). An important aspect of any
screening technique is the ability to identify samples with
false-negative results resulting from either an insufficient amount of
starting DNA or the presence of inhibitors. The
-actin assay was
therefore used to determine whether the lack of an HPV signal (i.e.,
Ct = 50) could be due to the presence of
insufficient amounts of genomic DNA or the presence of inhibitors
rather than a lack of HPV infection. On the basis of an analysis of
approximately 5,000 archival smears, about 90% of which gave a
positive
-actin signal, it appears that the likelihood of finding an
HPV-positive signal in a
-actin-negative sample is relatively low
(data not shown).
The assay for HPV described here can be extended in a number of ways.
Additional HPV types can be identified by increasing the number of
probes. Presently, only up to three probes can be used simultaneously
in the same reaction mixture. Also, our results indicate that for
accurate quantitation, the number of probes per assay should be kept
down. In the present application of the 5' exonuclease assay, only a
single measurement from the amplification curve, the
Ct value, is being used. However, the remaining
parts of the curve also contain valuable information, e.g., information that can be used to calculate the overall efficiency of the
amplification. A more extensive analysis of the entire amplification
curve would yield valuable information, e.g., for evaluation of the
degree of inhibition of the individual PCRs and its effect on the
Ct value.
In summary, the fluorescent 5' exonuclease assay described here has a
number of advantages over the existing methodologies for HPV detection,
in particular, with respect to the very powerful quantitation ability.
This method may be applied to studies of a number of issues related to
the natural history of cervical cancer, such as the amounts of HPV in
high- and low-grade lesions.
 |
ACKNOWLEDGMENTS |
This study was supported by the Swedish Cancer Foundation, the
Beijer Foundation, and the National Institutes of Health (grant 1 RO:
CA61197-01A3).
We are grateful to Catharina Hemström-Nilsson for the SiHa cell
line, Margit Gustavsson for helping with the Pap staining, Marita
Möllenberg for organizational help, and Patrik Magnusson for
comments on this paper.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Genetics and Pathology, Unit of Medical Genetics, Box 589, University of Uppsala, S-751 23 Uppsala, Sweden. Phone: 46-18-4714909. Fax: 46-18-510792. E-mail: ulf.gyllensten{at}medgen.uu.se.
 |
REFERENCES |
| 1.
|
Beaudenon, S.,
D. Kremsdorf,
O. Croissant,
S. Jablonska,
S. Wain-Hobson, and G. Orth.
1986.
A novel type of human papillomavirus associated with genital neoplasias.
Nature
321:246-249[Medline].
|
| 2.
|
Bonnez, W.
1993.
Taxonomy of the human papillomaviruses.
Clin. Infect. Dis.
17:1080[Medline].
|
| 3.
|
Bosch, F. X.,
M. M. Manos,
N. Munoz,
M. Sherman,
A. M. Jansen,
J. Peto,
M. H. Schiffman,
V. Moreno,
R. Kurman, and K. V. Shah.
1995.
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group.
J. Natl. Cancer. Inst.
87:796-802[Abstract/Free Full Text].
|
| 4.
|
Brown, D. R.,
J. T. Bryan,
H. Cramer, and K. H. Fife.
1993.
Analysis of human papillomavirus types in exophytic condylomata acuminata by hybrid capture and Southern blot techniques.
J. Clin. Microbiol.
31:2667-2673[Abstract/Free Full Text].
|
| 5.
|
Carter, J. J.,
L. A. Koutsky,
G. C. Wipf,
N. D. Christensen,
S.-K. Lee,
J. Kuypers,
N. Kiviat, and D. A. Galloway.
1996.
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university students.
J. Infect. Dis.
174:927-936[Medline].
|
| 6.
|
Chardonnet, Y.,
F. Bejui-Thivolet, and I. Guerin-Reverchon.
1992.
Human papillomavirus detection in cervical cells by in situ hybridization with biotinylated probes.
Cytopathology
3:341-350[Medline].
|
| 7.
|
Chua, K. L., and A. Hjerpe.
1995.
Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears.
Anal. Quant. Cytol. Histol.
17:221-229[Medline].
|
| 8.
|
De Roda Husman, A. M.,
J. M. Walboomers,
A. J. van den Brule,
C. J. Meijer, and P. J. Snijders.
1995.
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.
J. Gen. Virol.
76:1057-1062[Abstract/Free Full Text].
|
| 9.
|
de Villiers, E. M.
1989.
Heterogeneity of the human papillomavirus group.
J. Virol.
63:4898-4903[Free Full Text].
|
| 10.
|
de Villiers, E. M.
1994.
Human pathogenic papillomavirus types: an update.
Curr. Top. Microbiol. Immunol.
186:1-12[Medline].
|
| 11.
|
de Villiers, E. M.
1992.
Hybridization methods other than PCR: an update.
IARC Sci. Publ.
119:111-19.
|
| 12.
|
Galloway, D. A.
1994.
Papillomavirus capsids: a new approach to identify serological markers of H PV infection.
J. Natl. Cancer Inst.
86:474-475[Free Full Text].
|
| 13.
|
Gravitt, P. E., and M. M. Manos.
1992.
Polymerase chain reaction-based methods for the detection of human papillomavirus DNA.
IARC Sci. Publ.
119:121-133.
|
| 13a.
|
Gravitt, P. E.,
C. L. Peyton,
R. J. Apple, and C. M. Wheeler.
1998.
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.
J. Clin. Microbiol.
36:3020-3027[Abstract/Free Full Text].
|
| 14.
|
Holland, P. M.,
R. D. Abramson,
R. Watson, and D. H. Gelfand.
1991.
Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase.
Proc. Natl. Acad. Sci. USA
88:7276-7280[Abstract/Free Full Text].
|
| 15.
|
International Agency for Research on Cancer.
1995.
Human papillomaviruses.
In
IARC monographs on the evolution of carcinogenic risks to humans, vol. 64. International Agency for Research on Cancer, Lyon, France.
|
| 16.
|
Jacobs, M. V.,
A. J. van den Brule,
P. J. Snijders,
T. J. Helmerhorst,
C. J. Meijer, and J. M. Walboomers.
1996.
A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR.
J. Med. Virol.
49:223-229[Medline].
|
| 17.
|
Josefsson, A.,
P. K. E. Magnusson, and U. Gyllensten.
1998.
Human papillomavirus, p. 171-193.
In
R. S. Peeling, and P. F. Sparling (ed.), Methods in molecular medicine: molecular protocols for sexually transmitted diseases, vol. 11. .
|
| 18.
|
Kirnbauer, R.,
N. L. Hubbert,
C. M. Wheeler,
T. M. Becker,
D. R. Lowy, and J. T. Schiller.
1994.
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
J. Natl. Cancer Inst.
86:494-499[Abstract/Free Full Text].
|
| 19.
|
Lee, L. G.,
C. R. Connell, and W. Bloch.
1993.
Allelic discrimination by nick-translation PCR with fluorogenic probes.
Nucleic Acids Res.
21:3761-3766[Abstract/Free Full Text].
|
| 20.
|
Lindqvist, A. K.,
P. K. Magnusson,
J. Balciuniene,
C. Wadelius,
E. Lindholm,
M. E. Alarcon-Riquelme, and U. B. Gyllensten.
1996.
Chromosome-specific panels of tri- and tetranucleotide microsatellite markers for multiplex fluorescent detection and automated genotyping: evaluation of their utility in pathology and forensics.
Genome Res.
6:1170-1176[Abstract/Free Full Text].
|
| 21.
|
Livak, K. J.,
J. Marmaro, and J. A. Todd.
1995.
Towards fully automated genome-wide polymorphism screening.
Nat. Genet.
9:341-342[Medline].
|
| 22.
|
Lorincz, A.
1998.
Hybrid capture.
Clin. Chem.
44(6 Pt 1):1363[Free Full Text]. (Letter and comment.)
|
| 23.
|
Lorincz, A. T.
1996.
Molecular methods for the detection of human papillomavirus infection.
Obstet. Gynecol. Clin. N. Am.
23:707-730[Medline].
|
| 24.
|
Lorincz, A. T.,
A. P. Quinn,
W. D. Lancaster, and G. F. Temple.
1987.
A new type of papillomavirus associated with cancer of the uterine cervix.
Virology
159:187-190[Medline].
|
| 25.
|
Maniatis, T.,
E. F. Fritsch, and J. Sambrook.
1989.
Molecular cloning: a laboratory manual, 2nd ed, Appendix E3.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 26.
|
Manos, M. M.,
Y. Ting,
D. K. Wright,
A. J. Lewis,
T. R. Broker, and S. M. Wolinsky.
1989.
The use of polymerase chain reaction amplification for the detection of genital human papillomavirus.
Cancer Cells
7:209-214.
|
| 27.
|
Meyer, T.,
R. Arndt,
E. Stockfleth,
H. T. Flammann,
H. Wolf, and U. Reischl.
1995.
Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe.
BioTechniques
19:632-639[Medline].
|
| 28.
|
Pizzighella, S.,
G. Pisoni,
F. Bevilacqua,
A. Vaona, and G. Palu.
1995.
Simultaneous polymerase chain reaction detection and restriction typing for the diagnosis of human genital papillomavirus infection.
J. Virol. Methods
55:245-256[Medline].
|
| 29.
|
Pizzighella, S.,
M. Rassu,
I. Piacentini,
B. Maschera, and G. Palu.
1993.
Polymerase chain reaction amplification and restriction enzyme typing as an accurate and simple way to detect and identify human papillomaviruses.
J. Med. Microbiol.
39:33-38[Abstract].
|
| 30.
|
Roden, R. B. S.,
H. L. Greenstone,
R. Kirnbauer,
F. P. Booy,
J. Jessie,
D. R. Lowy, and J. T. Schiller.
1996.
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
J. Virol.
70:5875-5883[Abstract].
|
| 31.
|
Southern, E. M.
1975.
Detection of specific sequences among DNA fragments separated by gel electrophoresis.
J. Mol. Biol.
98:503-517[Medline].
|
| 32.
|
Swan, D. C.,
R. A. Tucker,
B. P. Holloway, and J. P. Icenogle.
1997.
A sensitive, type-specific, fluorogenic probe assay for detection of human papillomavirus DNA.
J. Clin. Microbiol.
35:886-891[Abstract].
|
| 33.
|
Unger, E. R.,
S. D. Vernon,
W. W. Thoms,
R. Nisenbaum,
C. O. Spann,
I. R. Horowitz,
J. P. Icenogle, and W. C. Reeves.
1995.
Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer.
J. Infect. Dis.
172:1184-1190[Medline].
|
| 34.
|
Van Den Brule, A. J.,
J. M. Walboomers,
M. Du Maine,
P. Kenemans, and C. J. Meijer.
1991.
Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia.
Int. J. Cancer
48:404-408[Medline].
|
| 35.
|
Ylitalo, N.,
T. Bergstrom, and U. Gyllensten.
1995.
Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization.
J. Clin. Microbiol.
33:1822-1828[Abstract].
|
Journal of Clinical Microbiology, March 1999, p. 490-496, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tabora, N., Ferrera, A., Bakkers, J. M. J. E., Massuger, L. F. A. G., Melchers, W. J. G.
(2008). High HPV 16 Viral Load is Associated with Increased Cervical Dysplasia in Honduran Women. Am J Trop Med Hyg
78: 843-846
[Abstract]
[Full Text]
-
Boulet, G A V, Schrauwen, I, Sahebali, S, Horvath, C, Depuydt, C E, Vereecken, A, Broeck, D V., Van Marck, E A, Bogers, J J
(2007). Correlation between laminin-5 immunohistochemistry and human papillomavirus status in squamous cervical carcinoma. J. Clin. Pathol.
60: 896-901
[Abstract]
[Full Text]
-
Fontaine, J., Gravitt, P., Duh, L.-M., Lefevre, J., Pourreaux, K., Hankins, C., Coutlee, F., The Canadian Women's HIV Study Group,
(2005). High Level of Correlation of Human Papillomavirus-16 DNA Viral Load Estimates Generated by Three Real-time PCR Assays Applied on Genital Specimens. Cancer Epidemiol. Biomarkers Prev.
14: 2200-2207
[Abstract]
[Full Text]
-
Oh, T. J., Kim, C. J., Woo, S. K., Kim, T. S., Jeong, D. J., Kim, M. S., Lee, S., Cho, H. S., An, S.
(2004). Development and Clinical Evaluation of a Highly Sensitive DNA Microarray for Detection and Genotyping of Human Papillomaviruses. J. Clin. Microbiol.
42: 3272-3280
[Abstract]
[Full Text]
-
Flores-Munguia, R., Siegel, E., Klimecki, W. T., Giuliano, A. R.
(2004). Performance Assessment of Eight High-Throughput PCR Assays for Viral Load Quantitation of Oncogenic HPV Types. J. Mol. Diagn.
6: 115-124
[Abstract]
[Full Text]
-
Moberg, M., Gustavsson, I., Gyllensten, U.
(2003). Real-Time PCR-Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer. J. Clin. Microbiol.
41: 3221-3228
[Abstract]
[Full Text]
-
Borg, I., Rohde, G., Loseke, S., Bittscheidt, J., Schultze-Werninghaus, G., Stephan, V., Bufe, A.
(2003). Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J
21: 944-951
[Abstract]
[Full Text]
-
Iftner, T., Villa, L. L.
(2003). Chapter 12: Human Papillomavirus Technologies. J Natl Cancer Inst Monogr
2003: 80-88
[Abstract]
[Full Text]
-
Mackay, I. M., Arden, K. E., Nitsche, A.
(2002). Real-time PCR in virology. Nucleic Acids Res
30: 1292-1305
[Abstract]
[Full Text]
-
Szuhai, K., Sandhaus, E., Kolkman-Uljee, S. M., Lemaitre, M., Truffert, J.-C., Dirks, R. W., Tanke, H. J., Fleuren, G. J., Schuuring, E., Raap, A. K.
(2001). A Novel Strategy for Human Papillomavirus Detection and Genotyping with SybrGreen and Molecular Beacon Polymerase Chain Reaction. Am. J. Pathol.
159: 1651-1660
[Abstract]
[Full Text]
-
Gruber, F., Falkner, F. G., Dorner, F., Hämmerle, T.
(2001). Quantitation of Viral DNA by Real-Time PCR Applying Duplex Amplification, Internal Standardization, and Two-Color Fluorescence Detection. Appl. Environ. Microbiol.
67: 2837-2839
[Abstract]
[Full Text]
-
Grüntzig, V., Nold, S. C., Zhou, J., Tiedje, J. M.
(2001). Pseudomonas stutzeri Nitrite Reductase Gene Abundance in Environmental Samples Measured by Real-Time PCR. Appl. Environ. Microbiol.
67: 760-768
[Abstract]
[Full Text]
-
Ylitalo, N., Josefsson, A., Melbye, M., Sörensen, P., Frisch, M., Andersen, P. K., Sparén, P., Gustafsson, M., Magnusson, P., Pontén, J., Gyllensten, U., Adami, H.-O.
(2000). A Prospective Study Showing Long-Term Infection with Human Papillomavirus 16 before the Development of Cervical Carcinoma in Situ. Cancer Res.
60: 6027-6032
[Abstract]
[Full Text]